PDS BIOTECHNOLOGY CORPORATION PDSB 深 沪
等待开盘 09-18 09:30:00 美东时间
1.15
-0.050
-4.17%
华盛通- 最 高1.21
- 今 开1.20
- 成交量 33.13万股
- 最 低 1.15
- 昨 收 1.20
- 总市值 5256.65万
- 52周最高 4.29
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 0.8505
- 委 比 -66.42%
- 总股本 4571.00万
- 历史最高 17.85
- 量 比 0.84
- 振 幅 5.00%
- 历史最低 0.615
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【一周科技动态】AWS新叙事，AMZN马上新高？GOOGL如何成为本周大赢家
涨跌纷纭——一周大科技表现 本周宏观主线： 投资者对9月的历史性弱势保持警惕，该月往往是股市表现最差的月份。重大事件包括Russell指数的重构初步公告，以及...
09-05 15:39
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PDS Biotechnology Corporation will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-10, 2025, in New York and virtually. CEO Frank Bedu-Addo, Ph.D., and CFO Lars Boesgaard will meet with investors. PDS Biotech, a late-stage immunotherapy company, is advancing its lead program PDS0101 (Versamune® HPV) in combination with pembrolizumab for advanced HPV16-positive head and neck cancers.
09-02 12:00
英伟达迎来一群劲敌
原标题：英伟达迎来一群劲敌 近期发布的超以太网（Ultra Ethernet，简称UE）1.0规范，为未来人工智能（AI）和高性能计算（HPC）系统定义了一套...
09-01 16:17
英伟达韩松团队新作：具有后神经架构搜索的高效语言模型
时令 发自 凹非寺 量子位 | 公众号 QbitAI 英伟达开源又放大招了！ 韩松团队推出了一款全新的基于后神经架构搜索的高效语言模型——Jet-Nemotr...
08-26 16:11
PDS Biotechnology Announces Promising Phase 2 Trial Results
PDS Biotechnology ( ($PDSB) ) just unveiled an announcement. On August 25, 2025...
08-25 20:58
PDS Biotechnology Reports Median Overall Survival Of 39.3 Months In HPV16-Positive Head And Neck Cancer Patients
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*VERSATILE-003 Phase 3 trial in
08-25 20:34
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
PDS Biotech announced final topline survival data from the VERSATILE-002 Phase 2 trial, showing a median overall survival (mOS) of 39.3 months in HPV16-positive recurrent/metastatic head and neck squamous cell cancer (HNSCC) patients treated with PDS0101 + pembrolizumab. This compares favorably to the best published mOS of 17.9 months with standard pembrolizumab or pembrolizumab + chemotherapy. The trial enrolled 53 patients, with durable surviva...
08-25 12:30
Piper Sandler Maintains Overweight on Precision Drilling, Raises Price Target to $74
Piper Sandler analyst Derek Podhaizer maintains Precision Drilling (NYSE:PDS) with a Overweight and raises the price target from $72 to $74.
08-14 23:07
PDS Biotechnology Q2 EPS $(0.21) Beats $(0.23) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 9.87 percent. This is a 8.7 percent increase over losses of $(0.23) per share from
08-13 19:00
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
